ASH 2022 | LOTIS-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with DLBCL
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the ongoing LOTIS-9 clinical trial (NCT05144009) which is evaluating the safety and efficacy of loncastuximab tesirine in combination with rituximab (Lonca-R) in untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL). In this study, the fitness and frailty of patients will be assessed using the simplified geriatric assessment (sGA). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
ADC Therapeutics: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Iksuda: Consultancy; MonteRosa: Consultancy; Merck: Consultancy; Abbvie/GenMab: Consultancy; Calithera: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; SeaGen: Consultancy.
